Prostate Cancer Diagnostics Market By Type, Companies, Forecast by 2027
Prostate Cancer Diagnostics Market will be US$ 7.5 Billion by 2027. Forcast By Type, End Users, Regions (North America & Latin America, Europe, Asia, Africa), Company Analysis.
By: Renub Research
In earlier times, prostate cancer has been diagnosed with DRE, i.e Digital Rectal Examination and PSA blood test, most commonly called Prostate-specific antigen and TRUS, known as Transrectal Ultrasound-guided biopsy. TRUS is the golden standard examination to confirm the diagnosis in all clinical circumstances in today's time. The Diagnostics Market Size for Prostate Cancer World over was US$ 1.6 Billion in 2020.
Among regions, the most impacted and higher cases of prostate cancer are the North American region, followed by European and Asia-Pacific regions. COVID-19 pandemic has transformed the market landscape. It has impacted almost every sector across the nations due to restrictions, lockdowns, and bard on transportation. Many surgeries have been postponed because of this pandemic. And as per our study, there would be a surge in this market post-pandemic recovery. As per this research report, Global Prostate Cancer Diagnostics Industry is expected to grow with a double-digit staggering CAGR of 24.69% during 2020-2027.
About the Company:
Renub Research is a Market Research and Consulting Company. We have more than 10 years of experience especially in international Business-to-
Phone No: +1 678-302-0700 (USA) | +91–120–421–
Follow the link for the full report with detailed TOC and list of figures and tables: https://www.renub.com/